Концентрация липополисахарид-связывающего белка и пресепсина у пациентов с вирусным поражением легких SARS-CoV-2, проживающих в Республике Крым
И.А. Яцков1, В.А. Белоглазов1, А.В. Кубышкин1, А.П.Николаева1, Е.Ю. Зяблицкая1, Ю.Е. Куницкая1, Э.Н. Лавренчук21 Медицинская академия имени С.И.Георгиевского Федерального государственного автономного образовательного учреждения высшего образования «Крымский федеральный университет имени В.И.Вернадского» Министерства науки и высшего образования Российской Федерации: 295007, Россия, Республика Крым, Симферополь, просп. Академика Вернадского, 4
2 Государственное бюджетное учреждение здравоохранения Республики Крым «Республиканская клиническая больница имени Н.А.Семашко»: 295017, Россия, Республика Крым, Симферополь, ул. Киевская, 69
Antimicrobial Stewardship Using Biomarkers: Accumulating Evidence for the Critically Ill
Evdoxia Kyriazopoulou 1 and Evangelos J. Giamarellos-Bourboulis 2,*1 2nd Department of Critical Care Medicine, National and Kapodistrian University of Athens, 12462 Athens, Greece; ekyri@med.uoa.gr
2 4th Department of Internal Medicine, National and Kapodistrian University of Athens, 12462 Athens, Greece
* Correspondence: egiamarel@med.uoa.gr; Tel.: +30-210-5831994
A simple prognostic score based on troponin and presepsin for COVID-19 patients admitted to the emergency department: a single-center pilot study
Paola Dell’Aquila1; Pasquale Raimondo2; Daniele Orso3; Paola De Luca1; Pietro Pozzessere1; Carmen Vita Parisi1; Tiziana Bove3; Luigi Vetrugno3; Salvatore Grasso2; Vito Procacci1.1 Department of Emergency Medicine, University Hospital of Bari, Bari, Italy;
2 Department of Emergency and Organ Transplant, University of Bari Aldo Moro, Bari, Italy;
3 Department of Medicine, University of Udine, Udine, Italy & Department of Anesthesia and Intensive Care Medicine, ASUFC Hospital of Udine, Udine, Italy.
Presepsin value predicts the risk of developing severe/critical COVID-19 illness: results of a pooled analysis
Giuseppe Lippi*, Fabian Sanchis-Gomar and Brandon M. Henry*Corresponding author: Prof. Giuseppe Lippi, Section of Clinical Biochemistry, University Hospital of Verona, Piazzale L.A. Scuro, 10, 37134 Verona, Italy, Phone: 0039 045 8122970, Fax: 0039 045 8124308, E-mail: giuseppe.lippi@univr.it. https://orcid.org/0000- 0001-9523-9054
Fabian Sanchis-Gomar, Department of Physiology, Faculty of Medicine, University of Valencia and INCLIVA Biomedical Research Institute, Valencia, Spain
Brandon M. Henry, Cardiac Intensive Care Unit, The Heart Institute, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, USA
Type 1 inflammatory endotype relates to low compliance, lung fibrosis, and severe complications in COVID-19
Takehiro Hasegawaa, *, Atsushi Nakagawab, Kohjin Suzukic, Kazuto Yamashitad, Saya Yamashitae, Niina Iwanagad, Eiya Tamadad, Kenta Nodad, Keisuke Tomiiba Sysmex R&D Centre Europe GmbH, Research and Development Division, Falkenried 88, 20251 Hamburg, Germany b Kobe City Medical Centre General Hospital, 2-1-1, Minamimachi, Minatojima, Chuo Ward, Kobe, Japan
c Sysmex System Technology Laboratories, 4-4-4, Takatsuka-dai, Nish Ward, Kobe, Japan
d Sysmex Central Research Laboratories, 4-4-4, Takatsuka-dai, Nish Ward, Kobe, Japan
e Sysmex Business Incubation Department, 4-4-4, Takatsuka-dai, Nish Ward, Kobe, Japan
Presepsin as a Novel Biomarker in predicting Inhospital Mortality in COVID-19 Pneumonia Patients
Hebatallah Hany Assal*, MD., Hebatallah.Assal@kasralainy.edu.eg, Safaa Abdelrahman, MD., safaa.mohamed5@gmail.com, Maha AlyAlden Abdelbasset, MD., maha.aly@gmail.com, Mai Abdelaziz, MD., maiabdelaziz1979@gmail.com, Irene Mohamed Sabry*, MD., irene.sabry@yahoo.com, Marwa Moawad Shaban*, MD., marwamoawad@ymail.comCorrespondence:
Hebatallah Hany Assal, MD, Hebatallah.Assal@kasralainy.edu.eg, Tel: 01223939861
Address: Department of Chest Medicine, Faculty of Medicine, Cairo University, Al Kasr Al Aini, Old Cairo Cairo,11956, Egypt
Plasma Soluble CD14 Subtype Levels Are Associated With Clinical Outcomes in Critically Ill Subjects With Coronavirus Disease 2019
F. Linzee Mabrey, MD1, Eric D. Morrell, MD1, Pavan K. Bhatraju, MD, MSc1, Neha A. Sathe, MD1, Sana S. Sakr, PhD1, Sharon K. Sahi, BS1, T. Eoin West, MD, MPH1, Carmen Mikacenic, MD2, Mark M. Wurfel, MD, PhD1Presepsin as a Predictive Biomarker of Severity in COVID-19: A Systematic Review
Sibtain Ahmed1, Maheen Mansoor2, Muhammad S Shaikh3, Imran Siddiqui41,3,4 Department of Pathology and Laboratory Medicine, Aga Khan University, Karachi, Pakistan
2 Department of Medical College, Aga Khan University, Karachi, Pakistan
Corresponding Author: Sibtain Ahmed, Department of Pathology and Laboratory Medicine, Aga Khan University, Karachi, Pakistan, e-mail: sibtain.ahmed@aku.edu
Presepsin as a predictive biomarker of severity in COVID-19: a case series
Ai Fukada1, Yutaro Kitagawa1, Masaru Matsuoka1, Jun Sakai2, Kazuo Imai2Tarumoto Norihito2, Yuta Orihara1, Rieko Kawamura1, Shinichi Takeuchi1
Shigefumi Maesaki2, Takuya Maeda1, 3
1Department of Clinical Laboratory, Saitama Medical University Hospital, Saitama, Japan
2 Department of Infectious Disease and Infection Control, Saitama Medical University, Saitama, Japan3Department of Laboratory Medicine, Saitama Medical University, Saitama, Japan
Пресепсин и стратификация рисков у пациентов с SARS-CoV-2 (COVID-19)
Presepsin in risk stratification of SARS-CoV-2 patientsClinica Chimica Acta Available online 22 April 2020
Martina Zaninotto aMonica Maria Mion aChiara Cosmaa Daniela Rinaldi aMarioPlebaniab
https://doi.org/10.1016/j.cca.2020.04.020Get rights and content